Takeaway

• Tirzepatide (TZP) at all doses was associated with significant and superior improvements in glycemic control and weight loss compared with semaglutide (SEMA) as an adjunct to metformin in patients with T2D.

Why this matters

• TZP is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist under development for treating T2D. ...